Diagnostic Kits/Bibliography by Resource Type: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
No edit summary
No edit summary
Line 52: Line 52:
** [[Diagnostic_Kits/Testing new ground|Highlights]]
** [[Diagnostic_Kits/Testing new ground|Highlights]]


*Holman, Christopher M., The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation. UMKC Law Review, Vol. 76, p. 295, 2007. Available at SSRN: http://ssrn.com/abstract=1090562
*Holman, Christopher M., ''The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation''. UMKC Law Review, Vol. 76, p. 295, 2007. Available at SSRN: http://ssrn.com/abstract=1090562


*Holman, C.M., 2008. GENETICS: Trends in Human Gene Patent Litigation. Science, 322(5899), 198-199.
*Holman, C.M., 2008. ''Genetics: Trends in Human Gene Patent Litigation''. Science, 322(5899), 198-199.
*J.D, M.A.H.P. & Munzer, S.R., Intellectual Property Rights in Genes and Gene Fragments: A Registration Solution for Expressed Sequence Tags. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=241236 [Accessed October 30, 2009].
*J.D, M.A.H.P. & Munzer, S.R., Intellectual Property Rights in Genes and Gene Fragments: A Registration Solution for Expressed Sequence Tags. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=241236 [Accessed October 30, 2009].


*Howlett, M.J. & Christie, A.F., An Analysis of the Approach of the European, Japanese and United States Patent Offices to Patenting Partial DNA Sequences (ESTs). SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=573184 [Accessed October 30, 2009].
*Howlett, M.J. & Christie, A.F., ''An Analysis of the Approach of the European, Japanese and United States Patent Offices to Patenting Partial DNA Sequences (ESTs)''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=573184 [Accessed October 30, 2009].


*Huys et al. Legal uncertainty in the area of genetic diagnostic testing. Nature Biotechnology (2009) vol. 27 (10) pp. 903-909.  Available at http://www.nature.com/nbt/journal/v27/n10/abs/nbt1009-903.html [accessed Nov 2 2009].
*Huys et al. ''Legal uncertainty in the area of genetic diagnostic testing''. Nature Biotechnology (2009) vol. 27 (10) pp. 903-909.  Available at http://www.nature.com/nbt/journal/v27/n10/abs/nbt1009-903.html [accessed Nov 2 2009].
**[[Diagnostic_Kits/Legal uncertainty in the area of genetic diagnostic testing|Highlights]]
**[[Diagnostic_Kits/Legal uncertainty in the area of genetic diagnostic testing|Highlights]]


*J.D, M.A.H.P. & Munzer, S.R., Intellectual Property Rights in Genes and Gene Fragments: A Registration Solution for Expressed Sequence Tags. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=241236 [Accessed October 30, 2009].
*J.D, M.A.H.P. & Munzer, S.R., ''Intellectual Property Rights in Genes and Gene Fragments: A Registration Solution for Expressed Sequence Tags''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=241236 [Accessed October 30, 2009].


*Jensen, K. & Murray, F., 2005. INTELLECTUAL PROPERTY: Enhanced: Intellectual Property Landscape of the Human Genome. Science, 310(5746), 239-240.   
*Jensen, K. & Murray, F., 2005. ''Intellectual Property: Enhanced: Intellectual Property Landscape of the Human Genome''. Science, 310(5746), 239-240.   
**[[Diagnostic_Kits/Intellectual Property Landscape of the Human Genome|Highlights]]
**[[Diagnostic_Kits/Intellectual Property Landscape of the Human Genome|Highlights]]


*Kalorama Information (Rosen). Diagnostic Test Service Commercialization: A Roadmap to Diagnostics in the 21st Century.  (2008)
*Kalorama Information (Rosen). ''Diagnostic Test Service Commercialization: A Roadmap to Diagnostics in the 21st Century''.  (2008)
**[[Diagnostic_Kits/Diagnostic Test Service Commercialization- A Roadmap to Diagnostics in the 21st Century|Highlights]]
**[[Diagnostic_Kits/Diagnostic Test Service Commercialization- A Roadmap to Diagnostics in the 21st Century|Highlights]]


*Kane, E., Molecules and Conflict: Cancer, Patents, and Women's Health. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=960772 Accessed October 30, 2009.
*Kane, E., ''Molecules and Conflict: Cancer, Patents, and Women's Health''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=960772 Accessed October 30, 2009.


*Kane, E., Patent-Mediated Standards in Genetic Testing. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1495820 Accessed October 29, 2009.
*Kane, E., ''Patent-Mediated Standards in Genetic Testing''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1495820 Accessed October 29, 2009.


*Kaye, J., Hawkins, N., and J. Taylor. (2007). Patents and translational research in genomics. Nature Biotechnology 25(7):739.
*Kaye, J., Hawkins, N., and J. Taylor. (2007). ''Patents and translational research in genomics''. Nature Biotechnology 25(7):739.
**[[Diagnostic_Kits/Patents and translational research in genomics|Highlights]]
**[[Diagnostic_Kits/Patents and translational research in genomics|Highlights]]


*Kling. Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine? EMBO reports (2007) vol. 8 (10) pp. 903-6. Accessed December 14, 2009 at http://www.nature.com/embor/journal/v8/n10/full/7401080.html
*Kling. ''Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine?'' EMBO reports (2007) vol. 8 (10) pp. 903-6. Accessed December 14, 2009 at http://www.nature.com/embor/journal/v8/n10/full/7401080.html
** [[Diagnostic Kits/Diagnosis or drug- Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine|Highlights]]
** [[Diagnostic Kits/Diagnosis or drug- Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine|Highlights]]


*Laakmann, A. Restoring the Genetic Commons: A "Common Sense" Approach to Biotechnology Patent in Restoring the Genetic Commons, Michigan Telecommunications and Technology Law Review 14 MITTLR 43 (2007).   
*Laakmann, A. ''Restoring the Genetic Commons: A "Common Sense" Approach to Biotechnology Patent in Restoring the Genetic Commons'', Michigan Telecommunications and Technology Law Review 14 MITTLR 43 (2007).   


*Lei et al. Patents versus patenting: implications of intellectual property protection for biological research. NATURE BIOTECHNOLOGY (2009) vol. 27 (1) pp. 36-40.  Available at: http://www.nature.com/nbt/journal/v27/n1/full/nbt0109-36.html
*Lei et al. ''Patents versus patenting: implications of intellectual property protection for biological research''. Nature Biotechnology (2009) vol. 27 (1) pp. 36-40.  Available at: http://www.nature.com/nbt/journal/v27/n1/full/nbt0109-36.html
** [[Diagnostic_Kits/Patents versus patenting: implications of intellectual property protection for biological research|Highlights]]
** [[Diagnostic_Kits/Patents versus patenting: implications of intellectual property protection for biological research|Highlights]]


*Macer, D.R.J., 2002. Patent or perish? An ethical approach to patenting human genes and proteins. The Pharmacogenomics Journal, 2(6), 361-366. Available at: http://www.nature.com/tpj/journal/v2/n6/full/6500140a.html [Accessed August 5, 2009].
*Macer, D.R.J., 2002. ''Patent or perish? An ethical approach to patenting human genes and proteins''. The Pharmacogenomics Journal, 2(6), 361-366. Available at: http://www.nature.com/tpj/journal/v2/n6/full/6500140a.html [Accessed August 5, 2009].


*McGill Centre for Intellectual Property Policy, 2005, Biotechnology and Intellectual Property: Reinventing the Commons: Workshop Report. Available at: www.cipp.mcgill.ca/data/events/00000017_en.pdf [Accessed November 20, 2009].
*McGill Centre for Intellectual Property Policy, 2005, ''Biotechnology and Intellectual Property: Reinventing the Commons: Workshop Report''. Available at: www.cipp.mcgill.ca/data/events/00000017_en.pdf [Accessed November 20, 2009].
**[[Diagnostic_Kits/Biotechnology and Intellectual Property Reinventing the Commons|Highlights]]
**[[Diagnostic_Kits/Biotechnology and Intellectual Property Reinventing the Commons|Highlights]]


*Merz, J.F. et al., 2002. Diagnostic testing fails the test. Nature, 415(6872), 577-579.(Garcia & Shimizu 1997) Available at: http://repository.upenn.edu/bioethics_papers/48/ [Accessed August 5, 2009].  
*Merz, J.F. et al., 2002. ''Diagnostic testing fails the test''. Nature, 415(6872), 577-579.(Garcia & Shimizu 1997) Available at: http://repository.upenn.edu/bioethics_papers/48/ [Accessed August 5, 2009].  
**[[Diagnostic_Kits/Diagnostic testing fails the test|Highlights]]
**[[Diagnostic_Kits/Diagnostic testing fails the test|Highlights]]


*Merz, J.F., 2002. Patents limit medical potential of sequencing. Nature, 419(6910), 878.  
*Merz, J.F., 2002. ''Patents limit medical potential of sequencing''. Nature, 419(6910), 878.  
**[[Diagnostic_Kits/Patents limit medical potential of sequencing|Highlights]]
**[[Diagnostic_Kits/Patents limit medical potential of sequencing|Highlights]]


*Merz, J.F., 1999. Disease Gene Patents: Overcoming Unethical Constraints on Clinical Laboratory Medicine. Clin Chem, 45(3), 324-330.(Merz 1999) Available at: http://www.clinchem.org/cgi/content/abstract/45/3/324 [Accessed August 5, 2009].
*Merz, J.F., 1999. ''Disease Gene Patents: Overcoming Unethical Constraints on Clinical Laboratory Medicine''. Clin Chem, 45(3), 324-330.(Merz 1999) Available at: http://www.clinchem.org/cgi/content/abstract/45/3/324 [Accessed August 5, 2009].
**[[Diagnostic_Kits/Disease Gene Patents|Highlights]]
**[[Diagnostic_Kits/Disease Gene Patents|Highlights]]


*Mills, A.E. & Tereskerz, P., 2008. DNA-based patents: an empirical analysis. Nat Biotech, 26(9), 993-995.   
*Mills, A.E. & Tereskerz, P., 2008. ''DNA-based patents: an empirical analysis''. Nat Biotech, 26(9), 993-995.   
**[[Diagnostic_Kits/DNA-based patents: an empirical analysis|Highlights]]
**[[Diagnostic_Kits/DNA-based patents: an empirical analysis|Highlights]]


*Mills, A.E. & Tereskerz, P.M., 2007. Changing patent strategies: what will they mean for the industry? Nat Biotech, 25(8), 867-868.
*Mills, A.E. & Tereskerz, P.M., 2007. ''Changing patent strategies: what will they mean for the industry?'' Nat Biotech, 25(8), 867-868.


*Morrison & Foerster : Legal Updates & News : Press Releases : Morrison & Foerster Represents ACON Laboratories in $175 Million Acquisition by Inverness Medical Innovations, Resolving Patent Litigation Between the Two Companies Over Rapid Diagnostic Techno. Available at: http://www.mofo.com/news/media/files/pr02058.html [Accessed August 5, 2009].  
*Morrison & Foerster : ''Legal Updates & News : Press Releases : Morrison & Foerster Represents ACON Laboratories in $175 Million Acquisition by Inverness Medical Innovations, Resolving Patent Litigation Between the Two Companies Over Rapid Diagnostic Techno''. Available at: http://www.mofo.com/news/media/files/pr02058.html [Accessed August 5, 2009].  
**[[Diagnostic_Kits/Morrison and Foerster Represents ACON Laboratories in $175 Million Acquisition by Inverness Medical Innovations|Highlights]]
**[[Diagnostic_Kits/Morrison and Foerster Represents ACON Laboratories in $175 Million Acquisition by Inverness Medical Innovations|Highlights]]


*Mueller, J.M., Public Access Versus Proprietary Rights in Genomic Information: What Is the Proper Role of Intellectual Property Rights? SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1367849 [Accessed October 30, 2009].
*Mueller, J.M., ''Public Access Versus Proprietary Rights in Genomic Information: What Is the Proper Role of Intellectual Property Rights?'' SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1367849 [Accessed October 30, 2009].


*Muller, A et. al., Protecting Biotechnological Inventions in Brazil and Abroad: Draft, Scope and Protecting Biotechnological Inventions in Brazil and Abroad: Draft, Scope, and Interpretation of Claims 2002, Albany Law Journal of Science and Technology, 13 ALBLJST 145 (2002).   
*Muller, A et. al., ''Protecting Biotechnological Inventions in Brazil and Abroad: Draft, Scope and Protecting Biotechnological Inventions in Brazil and Abroad: Draft, Scope, and Interpretation of Claims 2002'', Albany Law Journal of Science and Technology, 13 ALBLJST 145 (2002).   


*Nelson. The market economy, and the scientific commons. Research Policy (2004) vol. 33 (3) pp. 455-471
*Nelson. ''The market economy, and the scientific commons''. Research Policy (2004) vol. 33 (3) pp. 455-471
** [[Diagnostic_Kits/The market economy, and the scientific commons|Highlights]]
** [[Diagnostic_Kits/The market economy, and the scientific commons|Highlights]]


*Ouellette, L.L., Access to Bio-Knowledge: From Gene Patents to Biomedical Materials. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1431580 [Accessed October 29, 2009].
*Ouellette, L.L., ''Access to Bio-Knowledge: From Gene Patents to Biomedical Materials''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1431580 [Accessed October 29, 2009].


*Palombi. The Search for Alternatives to Patents in the 21st Century.(2009) pp. 1-42
*Paradise, J., ''European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent Controversy''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=897507 [Accessed October 30, 2009].
 
*Palombi. ''The Search for Alternatives to Patents in the 21st Century''.(2009) pp. 1-42
**[[Diagnostic_Kits/The Search for Alternatives to Patents in the 21st Century|Highlights]]
**[[Diagnostic_Kits/The Search for Alternatives to Patents in the 21st Century|Highlights]]


*Paradise, J., European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent Controversy. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=897507 [Accessed October 30, 2009].
*Palombi, L. ''The Search for Alternatives to Patents in the 21st Century''.  (2009)  Available at http://cgkd.anu.edu.au/menus/publications.php#palombi
 
*Palombi, L. The Search for Alternatives to Patents in the 21st Century.  (2009)  Available at http://cgkd.anu.edu.au/menus/publications.php#palombi
** [[Diagnostic_Kits/The Search for Alternatives to Patents in the 21st Century|Highlights]]
** [[Diagnostic_Kits/The Search for Alternatives to Patents in the 21st Century|Highlights]]


*Phillips, K.a., Van Bebber, S. & Issa, A.M., 2006. Diagnostics and biomarker development: priming the pipeline. Nature reviews. Drug discovery, 5(6), 463-9.  
*Phillips, K.a., Van Bebber, S. & Issa, A.M., 2006. ''Diagnostics and biomarker development: priming the pipeline''. Nature reviews. Drug discovery, 5(6), 463-9.  
** [[Diagnostic_Kits/Diagnostics and biomarker development- priming the pipeline|Highlights]]
**[[Diagnostic_Kits/Diagnostics and biomarker development- priming the pipeline|Highlights]]


*Pressman, L. et al., 2006. The licensing of DNA patents by US academic institutions: an empirical survey. Nat Biotech, 24(1), 31-39
*Pressman, L. et al., 2006. ''The licensing of DNA patents by US academic institutions: an empirical survey''. Nat Biotech, 24(1), 31-39
**[[Diagnostic_Kits/The licensing of DNA patents by US academic institutions|Highlights]]
**[[Diagnostic_Kits/The licensing of DNA patents by US academic institutions|Highlights]]


*Shapiro, C., Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard-Setting, 2001, Innovation Policy and the Economy (Vol. I) (Jaffe, Adam B. et al., eds), pp. 119-150, MIT Press, Available at: http://faculty.haas.berkeley.edu/shapiro/thicket.pdf [Accessed December 6, 2009]
*Shapiro, C., ''Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard-Setting'', 2001, Innovation Policy and the Economy (Vol. I) (Jaffe, Adam B. et al., eds), pp. 119-150, MIT Press, Available at: http://faculty.haas.berkeley.edu/shapiro/thicket.pdf [Accessed December 6, 2009]


*Torrance, A.W., Patenting Human Evolution. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1300615 [Accessed October 30, 2009].
*Torrance, A.W., ''Patenting Human Evolution''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1300615 [Accessed October 30, 2009].


*Verbeure, B. et al., 2006. Patent pools and diagnostic testing. Trends in Biotechnology, 24(3), 115-120.(Verbeure et al. 2006) Available at: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TCW-4J4HK5P-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=8c0fd5a6f1431a3cbfc9ff2f37470c3b [Accessed August 8, 2009].  
*Verbeure, B. et al., 2006. ''Patent pools and diagnostic testing. Trends in Biotechnology'', 24(3), 115-120.(Verbeure et al. 2006) Available at: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TCW-4J4HK5P-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=8c0fd5a6f1431a3cbfc9ff2f37470c3b [Accessed August 8, 2009].  
**[[Diagnostic_Kits/Patent pools and diagnostic testing|Highlights]]
**[[Diagnostic_Kits/Patent pools and diagnostic testing|Highlights]]


*Verbeure, B., Matthijs, G. & Van Overwalle, G., 2005. Analysing DNA patents in relation with diagnostic genetic testing. Eur J Hum Genet, 14(1), 26-33. Available at: http://www.nature.com/ejhg/journal/v14/n1/full/5201503a.html [Accessed August 11, 2009].  
*Verbeure, B., Matthijs, G. & Van Overwalle, G., 2005. ''Analysing DNA patents in relation with diagnostic genetic testing''. Eur J Hum Genet, 14(1), 26-33. Available at: http://www.nature.com/ejhg/journal/v14/n1/full/5201503a.html [Accessed August 11, 2009].  
**[[Diagnostic_Kits/Analysing DNA patents in relation with diagnostic genetic testing|Highlights]]
**[[Diagnostic_Kits/Analysing DNA patents in relation with diagnostic genetic testing|Highlights]]


*Walsh JP, Arora A, Cohen WM. Effects of research tool patents and licensing on biomedical innovation. In: Cohen WM, Merrel SA, (editors). Patents in the knowledge-based economy. Washington (DC): The National Academies Press; 2003. p. 285-340.
*Walsh JP, Arora A, Cohen WM. ''Effects of research tool patents and licensing on biomedical innovation''. In: Cohen WM, Merrel SA, (editors). Patents in the knowledge-based economy. Washington (DC): The National Academies Press; 2003. p. 285-340.
 
*Walsh, J. , Cho, C. & Cohen, W.M. Patents, Material Transfers and Access to Research Inputs in Biomedical Research (Final Report to the National Academy of Sciences' Committee [on] Intellectual Property Rights in Genomic and Protein-Related Research Inventions, 20 September 2005).  


*Wilson et al., Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation, 81 Clinical Pharmacology & Therapeutics 153 (2007).
*Wilson et al., Biomarker Development, ''Commercialization, and Regulation: Individualization of Medicine Lost in Translation'', 81 Clinical Pharmacology & Therapeutics 153 (2007).


*Wolrad Prinz zu Waldeck und Pyrmont, Research Tool Patents After Integra v. Merck—Have They Reached a Safe Harbor?, 14 Mich. Telecomm. Tech. L. Rev. 367 (2008), available at http://www.mttlr.org/volfourteen/waldeck.pdf
*Wolrad Prinz zu Waldeck und Pyrmont, ''Research Tool Patents After Integra v. Merck—Have They Reached a Safe Harbor?'', 14 Mich. Telecomm. Tech. L. Rev. 367 (2008), available at http://www.mttlr.org/volfourteen/waldeck.pdf


==Blogs & Social Media==
==Blogs & Social Media==
Line 181: Line 179:
==Business Association' Publications==
==Business Association' Publications==


*The Economic Impact of Licensed Commercialized Inventions Originating in University Research, 1996-2007, Biotechnology Industry Organization (BIO) Available at http://www.bio.org/ip/techtransfer/BIO_final_report_9_3_09_rev_2.pdf.
*''The Economic Impact of Licensed Commercialized Inventions Originating in University Research'', 1996-2007, Biotechnology Industry Organization (BIO) Available at http://www.bio.org/ip/techtransfer/BIO_final_report_9_3_09_rev_2.pdf.


==Civil Society Organizations Publications==
==NGO Publications==


*American Civil Liberties Union : BRCA: Genes and Patents. Available at: http://www.aclu.org/freespeech/gen/39556res20090512.html [Accessed August 5, 2009].
*American Civil Liberties Union: ''BRCA: Genes and Patents''. Available at: http://www.aclu.org/freespeech/gen/39556res20090512.html [Accessed August 5, 2009].


== Declarations and Manifestos==
== Declarations and Manifestos==
Line 193: Line 191:
==Governmental Resources and Reports==
==Governmental Resources and Reports==


* Australian Law Reform Commission. Genes and ingenuity: gene patenting and human health report.  (2004) pp. 678.  Available at http://www.austlii.edu.au/au/other/alrc/publications/reports/99/.  Accessed 27 Jan 2010
* Australian Law Reform Commission. ''Genes and ingenuity: gene patenting and human health report''.  (2004) pp. 678.  Available at http://www.austlii.edu.au/au/other/alrc/publications/reports/99/.  Accessed 27 Jan 2010
** [[/Genes and ingenuity: gene patenting and human health report.|Highlights]]
** [[/Genes and ingenuity: gene patenting and human health report.|Highlights]]


* Ayme et al. Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics. European Journal of Human Genetics (2008) vol. 16 Suppl 1 pp. S10-9
* Ayme et al. ''Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics''. European Journal of Human Genetics (2008) vol. 16 Suppl 1 pp. S10-9
** [[/Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics|Highlights]]
** [[/Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics|Highlights]]


*Esther van Zimmeren et al. 2006.Bulletin of the World Health Organization - A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions? Available at: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000500013 [Accessed August 10, 2009].  
*Esther van Zimmeren et al. 2006. ''Bulletin of the World Health Organization - A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions?'' Available at: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000500013 [Accessed August 10, 2009].  
**[[Diagnostic_Kits/A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions|Highlights]]
**[[Diagnostic_Kits/A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions|Highlights]]


*National Institutes of Health (NIH), Public Health Service, DHHS, NIH Principles and Guidelines for Sharing of Biomedical Resources -- Final (December 1999) Available at: http://www.ott.nih.gov/policy/research_tool.aspx
*National Institutes of Health (NIH), ''Public Health Service, DHHS, NIH Principles and Guidelines for Sharing of Biomedical Resources -- Final'' (December 1999) Available at: http://www.ott.nih.gov/policy/research_tool.aspx
**[[Diagnostic_Kits/NIH Principles and Guidelines for Sharing of Biomedical Resources|Highlights]]
**[[Diagnostic_Kits/NIH Principles and Guidelines for Sharing of Biomedical Resources|Highlights]]


*National Research Council of the National Academies — Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation. Reaping the benefits of genomic and proteomic research: intellectual property rights, innovation, and public health. Washington (DC): The National Academies Press; 2005. Available from http://www.nap.edu/catalog/11487.html, Also Available from: http://books.google.com/books?id=crZWVfYNmtgC&lpg=PP1&ots=jaiZTMGZOU&dq=Reaping%20the%20Benefits%20of%20Genomic%20and%20Proteomic%20Research%3A%20Intellectual%20Property%20Rights%2C%20Innovation%2C%20and%20Public%20Health&pg=PP1#v=onepage&q=&f=false
*National Research Council of the National Academies — Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation. ''Reaping the benefits of genomic and proteomic research: intellectual property rights, innovation, and public health''. Washington (DC): The National Academies Press; 2005. Available from http://www.nap.edu/catalog/11487.html, Also Available from: http://books.google.com/books?id=crZWVfYNmtgC&lpg=PP1&ots=jaiZTMGZOU&dq=Reaping%20the%20Benefits%20of%20Genomic%20and%20Proteomic%20Research%3A%20Intellectual%20Property%20Rights%2C%20Innovation%2C%20and%20Public%20Health&pg=PP1#v=onepage&q=&f=false


*Priorities for Personalized Medicine, Council of Advisors on Science and Technology (PCAST), September 2008 Available at: http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf
*Council of Advisors on Science and Technology (PCAST), ''Priorities for Personalized Medicine'', September 2008 Available at: http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf
**[[Diagnostic_Kits/Priorities for Personalized Medicine|Highlights]]
**[[Diagnostic_Kits/Priorities for Personalized Medicine|Highlights]]


*Secretary's Advisory Committee on Genetics, Health, and Society—Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests (Draft Report for Public Comment) [excerpts]. Biotechnology Law Report, 28(3), 417-442 (2009). Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011
*Secretary's Advisory Committee on Genetics, Health, and Society ''Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests'' (Draft Report for Public Comment) [excerpts]. Biotechnology Law Report, 28(3), 417-442 (2009). Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011
**[[Diagnostic_Kits/SACGHS_Gene_Patents_and_Licensing_Practices|Highlights]]
**[[Diagnostic_Kits/SACGHS_Gene_Patents_and_Licensing_Practices|Highlights]]


*'''*Secretary's Advisory Committee on Genetics, Health, and Society—Public Consultation Final Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests - September 17, 2009'''
*Secretary's Advisory Committee on Genetics, Health, and Society €”''Public Consultation Final Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests'' - September 17, 2009
**[[Diagnostic_Kits/SACGHS_Gene_Patents_and_Licensing_Practices_Final_Report|Highlights]]
**[[Diagnostic_Kits/SACGHS_Gene_Patents_and_Licensing_Practices_Final_Report|Highlights]]


*'''*Secretary's Advisory Committee on Genetics, Health, and Society—Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests - Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing.  (2009) Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011.'''
*Secretary's Advisory Committee on Genetics, Health, and Society ''€”Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests - Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing.'' (2009) Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011.
** [[SACGHS Appendix 1- Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing|highlights]]
** [[SACGHS Appendix 1- Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing|highlights]]


*'''*Secretary’s Advisory Committee on Genetics, Health, and Society, U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services, April 2008. Available at: http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf [Accessed July 8, 2009].'''
*'''*Secretary’s Advisory Committee on Genetics, Health, and Society, ''U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services'', April 2008. Available at: http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf [Accessed July 8, 2009].'''
**[[Diagnostic_Kits/SACGHS_U.S. System of Oversight of Genetic Testing|Highlights]]
**[[Diagnostic_Kits/SACGHS_U.S. System of Oversight of Genetic Testing|Highlights]]
*Walsh, J. , Cho, C. & Cohen, W.M. Patents, ''Material Transfers and Access to Research Inputs in Biomedical Research'' (Final Report to the National Academy of Sciences' Committee [on] Intellectual Property Rights in Genomic and Protein-Related Research Inventions, 20 September 2005).


==Market Reports==
==Market Reports==


*Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing: A Roadmap to Diagnostics in the 21st Century - market research report. Available at: http://www.reportlinker.com/p091997/Diagnostic-Test-Service-Commercialization-in-Multiplex-and-Esoteric-Testing-A-Roadmap-to-Diagnostics-in-the-21st-Century.html?utm_source=LivePR&utm_medium=pr&utm_campaign=LivePR [Accessed August 6, 2009].   
*''Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing: A Roadmap to Diagnostics in the 21st Century'' - market research report. Available at: http://www.reportlinker.com/p091997/Diagnostic-Test-Service-Commercialization-in-Multiplex-and-Esoteric-Testing-A-Roadmap-to-Diagnostics-in-the-21st-Century.html?utm_source=LivePR&utm_medium=pr&utm_campaign=LivePR [Accessed August 6, 2009].   
**[[Diagnostic_Kits/Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing|Highlights]]
**[[Diagnostic_Kits/Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing|Highlights]]


Line 241: Line 241:
* [[Diagnostic_Kits/Interviews#Andrew Torrance|Andrew Torrance]]
* [[Diagnostic_Kits/Interviews#Andrew Torrance|Andrew Torrance]]


'''Recommended'''
'''Considered'''
*[[http://74.125.95.132/search?q=cache:0AOgd7fUn38J:law.shu.edu/uploads/faculty/paradise_cv.pdf+Prof+Jordan+Paradise+at+Seton+Hall+Law&cd=1&hl=en&ct=clnk&gl=us|Prof Jordan Paradise]] at Seton Hall Law
*[[http://74.125.95.132/search?q=cache:0AOgd7fUn38J:law.shu.edu/uploads/faculty/paradise_cv.pdf+Prof+Jordan+Paradise+at+Seton+Hall+Law&cd=1&hl=en&ct=clnk&gl=us|Prof Jordan Paradise]] at Seton Hall Law
*[[http://www.law.ucla.edu/home/index.asp?page=571|Russ Korobkin]] at UCLA
*[[http://www.law.ucla.edu/home/index.asp?page=571|Russ Korobkin]] at UCLA
''' Upcoming? '''
* Jason Bobe
* Jason Bobe
* Dr. Joe Thakuria
* Dr. Joe Thakuria

Revision as of 16:16, 17 April 2010

Academic Articles and Papers

  • Cohen, W.M., Merrill, S.A. & Economy, N.R.C., 2003. Patents in the knowledge-based economy, National Academies Press.
    • Cook-Deegan, R., Chandrasekharan, S. & Angrist, M., 2009. The dangers of diagnostic monopolies. Nature, 458(7237), 405-406.
    • Highlights
  • Eisenberg, R. Noncompliance, 2008. Nonenforcement, Nonproblem? Rethinking the Anticommons in Biomedical Research. Houston Law Review Available at: # www.houstonlawreview.org/archive/downloads/45-4_pdf/03_​Eisenberg.pdf [Accessed November 20, 2009].
  • Garcia, L. & Shimizu, R., 1997. Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J. Clin. Microbiol., 35(6), 1526-1529.
  • Heller, M.A. & Eisenberg, R.A. Can patents deter innovation? The anticommons in biomedical research. Science 280, 698-701 (1998).
  • Hoag, H., 2004. Testing new ground. Nature, 429(6992), 682-3
  • Holman, Christopher M., The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation. UMKC Law Review, Vol. 76, p. 295, 2007. Available at SSRN: http://ssrn.com/abstract=1090562
  • Holman, C.M., 2008. Genetics: Trends in Human Gene Patent Litigation. Science, 322(5899), 198-199.
  • J.D, M.A.H.P. & Munzer, S.R., Intellectual Property Rights in Genes and Gene Fragments: A Registration Solution for Expressed Sequence Tags. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=241236 [Accessed October 30, 2009].
  • Jensen, K. & Murray, F., 2005. Intellectual Property: Enhanced: Intellectual Property Landscape of the Human Genome. Science, 310(5746), 239-240.
  • Kalorama Information (Rosen). Diagnostic Test Service Commercialization: A Roadmap to Diagnostics in the 21st Century. (2008)
  • Kaye, J., Hawkins, N., and J. Taylor. (2007). Patents and translational research in genomics. Nature Biotechnology 25(7):739.
  • Laakmann, A. Restoring the Genetic Commons: A "Common Sense" Approach to Biotechnology Patent in Restoring the Genetic Commons, Michigan Telecommunications and Technology Law Review 14 MITTLR 43 (2007).
  • McGill Centre for Intellectual Property Policy, 2005, Biotechnology and Intellectual Property: Reinventing the Commons: Workshop Report. Available at: www.cipp.mcgill.ca/data/events/00000017_en.pdf [Accessed November 20, 2009].
  • Merz, J.F., 2002. Patents limit medical potential of sequencing. Nature, 419(6910), 878.
  • Mills, A.E. & Tereskerz, P., 2008. DNA-based patents: an empirical analysis. Nat Biotech, 26(9), 993-995.
  • Mills, A.E. & Tereskerz, P.M., 2007. Changing patent strategies: what will they mean for the industry? Nat Biotech, 25(8), 867-868.
  • Morrison & Foerster : Legal Updates & News : Press Releases : Morrison & Foerster Represents ACON Laboratories in $175 Million Acquisition by Inverness Medical Innovations, Resolving Patent Litigation Between the Two Companies Over Rapid Diagnostic Techno. Available at: http://www.mofo.com/news/media/files/pr02058.html [Accessed August 5, 2009].
  • Muller, A et. al., Protecting Biotechnological Inventions in Brazil and Abroad: Draft, Scope and Protecting Biotechnological Inventions in Brazil and Abroad: Draft, Scope, and Interpretation of Claims 2002, Albany Law Journal of Science and Technology, 13 ALBLJST 145 (2002).
  • Nelson. The market economy, and the scientific commons. Research Policy (2004) vol. 33 (3) pp. 455-471
  • Paradise, J., European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent Controversy. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=897507 [Accessed October 30, 2009].
  • Palombi. The Search for Alternatives to Patents in the 21st Century.(2009) pp. 1-42
  • Phillips, K.a., Van Bebber, S. & Issa, A.M., 2006. Diagnostics and biomarker development: priming the pipeline. Nature reviews. Drug discovery, 5(6), 463-9.
  • Pressman, L. et al., 2006. The licensing of DNA patents by US academic institutions: an empirical survey. Nat Biotech, 24(1), 31-39
  • Shapiro, C., Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard-Setting, 2001, Innovation Policy and the Economy (Vol. I) (Jaffe, Adam B. et al., eds), pp. 119-150, MIT Press, Available at: http://faculty.haas.berkeley.edu/shapiro/thicket.pdf [Accessed December 6, 2009]
  • Walsh JP, Arora A, Cohen WM. Effects of research tool patents and licensing on biomedical innovation. In: Cohen WM, Merrel SA, (editors). Patents in the knowledge-based economy. Washington (DC): The National Academies Press; 2003. p. 285-340.
  • Wilson et al., Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation, 81 Clinical Pharmacology & Therapeutics 153 (2007).
  • Wolrad Prinz zu Waldeck und Pyrmont, Research Tool Patents After Integra v. Merck—Have They Reached a Safe Harbor?, 14 Mich. Telecomm. Tech. L. Rev. 367 (2008), available at http://www.mttlr.org/volfourteen/waldeck.pdf

Blogs & Social Media

Blogs

Twitter

http://twitter.com/100ideas/geneticdx - 8 experts on genetic/genomic diagnostics and personalized medicine

News

  • GEN- Genetic Engineering & Biotechnology News: Clinical Research & Diagnostics Channel (http://www.genengnews.com/transmed/)
    Content includes News, Articles, Tutorials, & Conferences/Meetings

Business Association' Publications

NGO Publications

Declarations and Manifestos

Governmental Resources and Reports

  • Ayme et al. Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics. European Journal of Human Genetics (2008) vol. 16 Suppl 1 pp. S10-9
  • Secretary's Advisory Committee on Genetics, Health, and Society Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests (Draft Report for Public Comment) [excerpts]. Biotechnology Law Report, 28(3), 417-442 (2009). Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011
  • Secretary's Advisory Committee on Genetics, Health, and Society €”Public Consultation Final Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests - September 17, 2009
  • Secretary's Advisory Committee on Genetics, Health, and Society €”Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests - Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011.
  • Walsh, J. , Cho, C. & Cohen, W.M. Patents, Material Transfers and Access to Research Inputs in Biomedical Research (Final Report to the National Academy of Sciences' Committee [on] Intellectual Property Rights in Genomic and Protein-Related Research Inventions, 20 September 2005).

Market Reports

Newspapers and Opinions

Databases and Statistics and Patents

Interviews

Completed

Considered